Shawn Singh
Chief Executive Officer and Director,
Vistagen Therapeutics
United States
Shawn Singh has served as Vistagen's CEO since 2009 and joined the Board of Directors in 2000; he has over 30 years of experience working with private and public biotechnology, medical device, and pharmaceutical companies, a venture capital firm, and a contract research and development organization (CRO), serving in numerous senior management roles. Before joining Vistagen as CEO, Mr. Singh served as President of Artemis Neuroscience before being acquired by the company, as Managing Principal of Cato BioVentures, a healthcare-focused venture capital firm, and as Chief Business Officer and General Counsel of Cato Research Ltd (now Allucent), a global CRO. Earlier, Mr. Singh assisted with the IPO of SciClone Pharmaceuticals (formerly NASDAQ: SCLN), a revenue-generating specialty pharmaceutical company, and served as its Chief Business Officer before departing to form Cato BioVentures with the founders of Cato Research. He began his career as a corporate finance attorney in the Silicon Valley offices of Morrison & Foerster LLP, with a transaction-focused practice involving emerging biotechnology and high-technology companies. Mr. Singh earned a B.A. degree, with honors, from the University of California, Berkeley, and a J.D. degree from the University of Maryland School of Law.
Suffix
JD
Sessions
-
10-Feb-2025Vistagen Therapeutics, Inc. (VTGN)
)
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}
){kind=logo}